This study found linked in Turnbuckle's thread on manipulating mitochondrial dynamics suggests that NR is broken down in the gut (cleaved by an enzyme). However, it also is a study on orally ingested NMN, not the patented, Chromadex version known as Niagen.
So what is the truth on this? Is it broken down into N+R and does taking Nicotinamide and D-Ribose result in the same effect, or does it not? Is there evidence to the contrary?
That is evidently not the case, as I explained previously here and in several other places. The cited study (Gross & Henderson PMID 6218262) started with singly-labeled NMN, degraded that into singly-labeled NR (along with singly-labeled NAM and NMN), and then used the resulting singly-labeled NR to do their study. (This is the confusion over NMN vs. NR between your description of the study, Nate, and Able's response). It's not clear to me that they can say with certainty that the "NR" they administered is actually pure NR, rather than a mixture that still contains NMN-derivatived labeled NAM and/or NMN. In any case, because this NR was only labeled at its carbonyl group, they could not trace the fate of the ribosyl moiety, and they also didn't track its fate in target tissues.
Both Frederick & Baur PMID 27508874 and Trammell & Brenner PMID 27721479, using doubly-labeled NR (with deuterium at the ribosyl C2 and 13C at the NAM carbonyl group), find that at least in the liver, a small amount of ingested NR is utilized intact. As reported by Trammell & Brenner PMID 27721479:
54% of the NAD+ and 32% of the NADP+ contained at least one heavy atom, while 5% of the NAD+ and 6% of the NADP+ incorporated both heavy atoms. Because >50% of hepatic NAD+ incorporates label before a rise in NAD+ accumulation, it is clear that the NAD+ pool is dynamic. As shown in Fig. 7c,d, the majority of hepatic Nam and MeNam following gavage of double-labelled NR incorporated a heavy atom, necessarily the 13C in Nam. Because NR drives increased NAD+ synthesis and ADPR production (Fig. 5), the liberated singly labelled Nam becomes incorporated into NMN and NAD+in competition with double labelled NR, thereby limiting subsequent incorporation of both labels into the NAD+ pool.
As I've indicated previously, it does appear likely that additional NR is broken down into NAM prior to entering the systemic circulation. None the less, both Trammell (in his thesis project — see Chapter 5, and especially Figures 5.8 and 5.9) and Frederick & Baur op cit both find doubly-labeled (intact NR-derived) NAD+ in the muscles after gavage and oral administration, respectively. (Note, in Fig. 5. 8, that more of the rise in NAD+ is accounted for by singly-labeled M+1 NAD+ (derived from NAM via salvage pathway after breakdown to NAM) than by doubly-labeled M+2 NAD+ (derived from intact NR); it looks as if a somewhat higher percentage is derived from intact NR after injection (Fig. 5.9), perhaps because it bypasses the intestine and the liver).
Moreover, the elevation in muscle NAD+ in Frederick & Baur PMID 27508874 can't come from uptake of circulating NAM, whether it's derived from broken-down NR or not, because these mice have their muscle NAMPT enzymes knocked out, and therefore can't make NAD+ from NAM — only from NMN or NR.
In any case, direct use of that small amount of circulating NR as an NAD+ precursor and NR-derived NAM may not be the full story on the ultimate effect on tissue NAD+ levels either: as Frederick & Baur PMID 27508874 report, despite only "minute" amounts of intact NR being incorporated into muscle NAD+, and despite their animals' muscles being unable to use NAM to synthesize NAD+,
To test whether NAM itself might account for some of the beneficial effects of NR treatment, we performed an additional experiment that included 3 weeks of NAM treatment. NAM-treated mice exhibited To test whether NAM itself might account for some of the beneficial effects of NR treatment, we performed an additional experiment that included 3 weeks of NAM treatment. NAM-treated mice exhibited intermediate phenotypes with regard to muscle performance and NAD+ levels [as compared with NR-supplemented and vehicle-treated animals] (Figures S5A–S5I).
Indeed, to a rough approximation the effects of NAM are here about half those of NR.
Now, I hasten to add that this can't be extrapolated to indicate the relative effects of NAM vs. NR in normal mice or humans: these were mice with the gene for NAMPT knocked out in their muscles, so they couldn't synthesize NAD+ from NAM directly in their muscles.
Resynthesis from NAM + R is unlikely to be the main explanation, first on a sheer stoichiometry and volume of distribution basis, but also because it's not clear the body even can synthesize NR from NAM + R: very little is known about NR biosynthesis, but the main known route is via the breakdown of NMN, not de novo biosynthesis. Indeed, in their paper on the discovery of the two known enzymes responsible for the production of NR and nicotinic acid riboside, the authors wrote:
We set out to determine the enzymes responsible for NR and NAR production. Because there is no biological precedent for nucleoside synthesis de novo and because NR and NAR accumulation appear to occur at the expense of NAD+ (Figs. 1 and 2), we considered the mechanisms by which NAD+ and related compounds could be broken down to NR.
Frederick and Baur propose several possible mechanisms in addition to direct muscle use of intact NR:
The correlation between the NAD content and the respiratory capacity of isolated mitochondria, even in cultured myotubes (Figure 4), supports the model that subtle changes in NAD can disproportionately modulate aerobic metabolism. It is important to note that NAD turnover may vary independently from NAD concentration and that small changes in average tissue concentration might reflect larger changes in specific cells or subcellular compartments.
It is also possible that intramuscular conversion of NAD into secondary messengers potently influences calcium homeostasis, which is both essential to muscle contraction and can independently modulate mitochondrial respiration (Cárdenas et al., 2010). Our results leave open the possibility that some of the functional improvements in NR-treated mNKO muscles are secondary to effects in other cell types. ... The observation that NAM treatment was sufficient to confer a partial effect in mNKO muscle supports the model that effects outside of differentiated fibers contribute to the benefits of NR. Such indirect activities may help to explain how oral NR administration clearly mitigates the severity of insults to a growing list of tissues in which robust NAD decrements were not observed before treatment (Brown et al., 2014; Cerutti et al., 2014; Khan et al., 2014; Xu et al., 2015). We also cannot exclude the possibility that NAM contributes slightly to the NAD pool in mNKO myofibers by inhibition of NAM-sensitive NAD consumers or via residual Nampt activity in fibers or fusing myoblasts.
I will myself note that effects on NADP(H) in C57BL/6 mice could also "help to explain how oral NR administration clearly mitigates the severity of insults to a growing list of tissues in which robust NAD+ decrements were not observed before treatment"
a